FOx BIOSYSTEMS , a company on the mission to revolutionize life science and pharmacological research with innovative real-time, analysis products and the Biosensors research group at KU Leuven, focused on developing innovative bio-molecular detection concepts and miniaturized analysis systems, announced a novel, label-free assay that can characterize the polyclonal antibody response against
KU Leuven’s Biosensors group develops first label-free assay characterizing COVID-19 antibodies directly in patient blood, using FOx BIOSYSTEMS platformThe White FOx FO-SPR instrument can rapidly analyze antibody kinetic profiles against SARS-CoV-2 spike proteins in serum and whole blood from COVID-19 patients.